"Hydroxyurea" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
| Descriptor ID |
D006918
|
| MeSH Number(s) |
D02.948.395
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydroxyurea".
Below are MeSH descriptors whose meaning is more specific than "Hydroxyurea".
This graph shows the total number of publications written about "Hydroxyurea" by people in this website by year, and whether "Hydroxyurea" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 4 | 2 | 6 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 2 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 1 | 2 |
| 2022 | 1 | 3 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxyurea" by people in Profiles.
-
Sharma D, Kozanoglu I, Ataga KI, Benachi A, B?y?kkurt S, Lanzkron S, Ozdogu H, Pancham S, Pecker LH, Robinson SE, Yilmaz Baran S, Howard J. Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel. Blood Adv. 2024 02 27; 8(4):1018-1029.
-
Guarino S, Lanzkron S. Evidence-Based Minireview: How to utilize new therapies for sickle cell disease. Hematology Am Soc Hematol Educ Program. 2022 12 09; 2022(1):283-285.
-
Menchaca AD, Style CC, Villella AD, Burdjalov M, Beyene TJ, Minneci PC, Olutoye OO. Pediatric Sickle Cell Disease Patients on Hydroxyurea Have Higher Rates of Surgical Splenectomy. J Surg Res. 2023 Mar; 283:798-805.
-
Chan KH, Rizvi SH, De Jesus-Rojas W, Stark JM, Mosquera RA, Prada-Ruiz AC, Gonzales T, Brown DL, Menon NM, Nguyen TT, Jon CK, Yadav A. Pulmonary hypertension screening in children with sickle cell disease. Pediatr Blood Cancer. 2023 01; 70(1):e29980.
-
Christian J, Lanzkron S, Naik RP. COVID-19 outcomes in sickle cell disease and sickle cell trait. Best Pract Res Clin Haematol. 2022 Sep; 35(3):101382.
-
Rizk S, Axelrod DJ, Olaosebikan R, Ballas SK. Case Series and Review of Hematological and Non-Hematological Malignancies in Aging Patients with Sickle Cell Disease in the Hydroxyurea Era. Hemoglobin. 2020 Sep; 44(5):303-306.
-
Pecker LH, Hussain S, Christianson MS, Lanzkron S. Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. Br J Haematol. 2020 12; 191(5):880-887.
-
Jabour SM, Beachy S, Coburn S, Lanzkron S, Eakin MN. The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease. J Racial Ethn Health Disparities. 2019 12; 6(6):1233-1243.
-
Su ZT, Segal JB, Lanzkron S, Ogunsile FJ. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017. Pharmacoepidemiol Drug Saf. 2019 09; 28(9):1246-1250.
-
Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018 Jul 19; 379(3):226-235.